Business
Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer
NASHVILLE, Tenn., May 20, 2026--Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, today announced a strategic collaboration with Pfizer Inc. to advance the development of Pfizer’s oncology portfolio through a science‑driven and scaled research program designed to bring promising therapies to patients faster and closer to home.
About this update from Pfizer, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1484,"height":255,"url":"https://media.zenfs.com/en/business-wire.com/cf48fe70737f21974714e7825801e944"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0DJwuGN6vfa2Ss1kKOeCsg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2NQ--/https://media.zenfs.com/en/business-wire.com/cf48fe70737f21974714e7825801e944","width":960,"height":165},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/a0ToTOPDJqEUtV_RW1xbpw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTExMA--/https://media.zenfs.com/en/business-wire.com/cf48fe70737f21974714e7825801e944","width":640,"height":110},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/LranGz1cntUCuZDLyqw_Aw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MTI-/https://media.zenfs.com/en/business-wire.com/cf48fe70737f21974714e7825801e944","width":1200,"height":206}},"lazy":false},{"type":"text","content":"Streamlining operational delivery for US-based oncology research to accelerate clinical trials and expand patient access","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"NASHVILLE, Tenn., May 20, 2026--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, today announced a strategic collaboration with Pfizer Inc. to advance the development of Pfizer’s oncology portfolio through a science‑driven and scaled research program designed to bring promising therapies to patients faster and closer to home.","length":438,"tagName":"p","attribs":{}},{"type":"text","content":"Central to the collaboration is SCRI’s Accelero™, a next-generation clinical trial delivery model designed to accelerate oncology drug development and expand patient access to innovative therapies in the community setting. By leveraging Accelero in this collaboration, SCRI and Pfizer aim to streamline trial operations, enhance site efficiency, and reduce burden for investigators and care teams.","length":397,"tagName":"p"},{"type":"text","content":"SCRI and Pfizer previously collaborated on three studies utilizing the Accelero model, which quickly expanded to more than ten, enabling faster study start-up, improved execution, and the efficient delivery of promising therapies to patients closer to home. Leading the fi...